Cancer Research UK on Google+ Cancer Research UK on Facebook Cancer Research UK on Twitter
 

Peter Johnson research projects

Researcher Peter Johnson profile image

University of Southampton
Southampton Cancer Research UK Centre
Somers Cancer Research Building, MP824
Southampton General Hospital
Southampton
SO16 6YD

CRUKD/07/063: A Cancer Research UK Phase I trial of the chimeric anti-CD40 monoclonal antibody Chi Lob 7/4 given iv weekly for 4 weeks in advanced malignancies refractory to conventional cancer treatment

Funding period: 01 April 2003 to 30 April 2016
Funding scheme: New Agents Committee Trials Funding
Funding committee: New Agents Committee

Abstract

Background

This is a Cancer Research UK Phase I clinical trial evaluating the safety, tolerability and biological effects of the chimeric anti-CD40 monoclonal antibody Chi Lob 7/4 given intravenously, weekly for 4 weeks in the treatment of patients with advanced malignancies refractory to conventional anti-cancer treatment. Patients with CD40 positive solid tumours or diffuse large B-cell non-Hodgkin's lymphoma will be entered into the trial. It is a 2 centre, dose escalation, Phase I study. 

Specific aims and objectives

The primary objectives of the trial are: to establish the maximum tolerated dose (MTD) of Chi Lob 7/4; to determine the biologically active dose; to determine and establish the toxicity profile of Chi Lob 7/4 and to identify the dose limiting toxicity (DLT); and to propose a safe dose for Phase II evaluation. 

The secondary objectives are: to examine the biological effects of Chi Lob 7/4 treatment; to examine the pharmacokinetics (PK) of treatment using ELISA measurement of serum Chi Lob 7/4 levels; and to examine any anti-tumour activity. If no dose-limiting toxicity (DLT) is observed after all patients have completed the study, the biologically active dose will be determined as that at which peripheral blood B-cells are reduced by the end of therapy (4 weeks post last infusion) to 10% or less of the starting number. 

Secondary end-points will include plasma cytokine levels, analysis of tumour infiltrating lymphocytes/mononuclear cells, and circulating APCs.